A Phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Beijing Avistone Biotechnology
This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.
Enrollment Form
This study is currently enrolling.